0001179110-20-004114.txt : 20200325
0001179110-20-004114.hdr.sgml : 20200325
20200325162219
ACCESSION NUMBER: 0001179110-20-004114
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200323
FILED AS OF DATE: 20200325
DATE AS OF CHANGE: 20200325
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Albers Jeffrey W.
CENTRAL INDEX KEY: 0001638474
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37359
FILM NUMBER: 20742402
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORP.
STREET 2: 215 FIRST STREET, SUITE 340/350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Blueprint Medicines Corp
CENTRAL INDEX KEY: 0001597264
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-374-7580
MAIL ADDRESS:
STREET 1: 45 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2020-03-23
0
0001597264
Blueprint Medicines Corp
BPMC
0001638474
Albers Jeffrey W.
C/O BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET
CAMBRIDGE
MA
02139
1
1
0
0
CEO and President
Common Stock
2020-03-23
4
M
0
20000
1.87
A
141434
D
Common Stock
2020-03-23
4
M
0
80
1.87
A
141514
D
Common Stock
2020-03-23
4
M
0
19920
8.80
A
161434
D
Common Stock
2020-03-23
4
S
0
484
55.34
D
160950
D
Common Stock
2020-03-23
4
S
0
3293
54.62
D
157657
D
Common Stock
2020-03-23
4
S
0
1936
53.54
D
155721
D
Common Stock
2020-03-23
4
S
0
2100
52.11
D
153621
D
Common Stock
2020-03-23
4
S
0
8850
51.30
D
144771
D
Common Stock
2020-03-23
4
S
0
3337
50.40
D
141434
D
Stock Option (Right to Buy)
1.87
2020-03-23
4
M
0
20000
0
D
2024-07-30
Common Stock
20000
173903
D
Stock Option (Right to Buy)
1.87
2020-03-23
4
M
0
80
0
D
2024-07-30
Common Stock
80
0
D
Stock Option (Right to Buy)
8.80
2020-03-23
4
M
0
19920
0
D
2025-02-10
Common Stock
19920
87170
D
Effected pursuant to a trading plan adopted on December 11, 2018 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.25 to $55.43 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.15 to $55.04 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.06 to $53.93 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.84 to $52.805 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.84 to $51.82 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.83 to $50.74 per share.
This option was granted on July 30, 2014 and is fully vested.
This option was granted on February 10, 2015 and is fully vested.
/s/ Christopher Frankenfield, Attorney-in-Fact
2020-03-25